To develop a therapeutic small molecule viral entry inhibitor as a medical countermeasure for filovirus infection
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $20,000,000 to $50,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
-
- Swee Teo swee.teo@nih.gov
- Catherine Bigger catherine.bigger@nih.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health is pursuing a cost-plus-fixed-fee contract with Arisan Therapeutics to advance product development of ARN-75092, a small-molecule therapeutic viral entry inhibitor for filovirus infection, with an estimated award date of 2026-07-01. ARN-75092 inhibits a viral glycoprotein attachment protein of Ebola virus (EBOV), Marburg virus (MARV), and Sudan virus (SUDV), protects mice against several of these viruses, and is positioned as a first-in-class therapeutic offering easier patient dosing, reduced cold chain requirements, and lower overall costs. The concept solicitation, approved under the 2025 Omnibus BAA Research Area 002, carries an estimated solicitation release date of 2025-07-01, NAICS 541715, and no set-aside.
The estimated award value range is $20 million to $50 million, with the final decision on the contract contingent on availability of funds and the outcome of negotiations with Arisan Therapeutics. Points of contact are Swee Teo, Contracting Officer (swee.teo@nih.gov), and Catherine Bigger (catherine.bigger@nih.gov), both at the National Institutes of Health.
Forecast text
The concept solicitation approved 2025 Omnibus BAA Research Area 002 proposal seeks to advance product development of ARN-75092 from Arisan Therapeutics. This is a small-molecule drug that inhibits a viral glycoprotein attachment protein of several members of the filovirus family (Ebola virus - EBOV, Marburg virus - MARV, and Sudan virus - SUDV). ARN-75092 protects mice against several of these viruses and is positioned to be a first-in-class therapeutic for these deadly hemorrhagic fever viruses that provides better treatment logistics in ease of dosing infected patients, reduced cold chain requirements, and lower overall costs. The final decision on a cost-plus-fixed-fee contract will be made based on the availability of funds and the outcome of contract negotiations with Arisan Therapeutics.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast